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Abstract
Background: The purpose of this study is to evaluate the dosimetric benefits of a proton arc technique for treating
tumors of the para-aortic lymph nodes (PALN).
Method: In nine patients, a proton arc therapy (PAT) technique was compared with intensity modulated radiation
therapy (IMRT) and proton beam therapy (PBT) techniques with respect to the planning target volume (PTV) and
organs at risk (OAR). PTV coverage, conformity index (CI), homogeneity index (HI) and OAR doses were compared.
Organ-specific radiation induced cancer risks were estimated by applying organ equivalent dose (OED) and normal
tissue complication probability (NTCP).
Results: The PAT techniques showed better PTV coverage than IMRT and PBT plans. The CI obtained with PAT was
1.19 ± 0.02, which was significantly better than that for the IMRT techniques. The HI was lowest for the PAT plan
and highest for IMRT. The dose to the OARs was always below the acceptable limits and comparable for all three
techniques. OED results calculated based on a plateau dose–response model showed that the risk of secondary
cancers in organs was much higher when IMRT or PBT were employed than when PAT was used. NTCPs of PAT to
the stomach (0.29 %), small bowel (0.69 %) and liver (0.38 %) were substantially lower than those of IMRT and PBT.
Conclusion: This study demonstrates that there is a potential role for PAT as a commercialized instrument in the
future to proton therapy.
Keywords: Proton arc therapy (PAT), Proton beam therapy (RBT), Intensity modulated radiation therapy (IMRT),
Organ equivalent doses (OED), Normal tissue complication probability (NTCP)
Introduction
New technologies in the delivery of radiation therapy have
included the use of intensity-modulated radiation therapy
(IMRT) or volumetric modulated arc therapy (VMAT) with
linear accelerators, as well as the development of proton
beam therapy (PBT), which has increased the ability to
maximize the dose to the tumor while sparing normal
structures. The VMAT approach has a number of potential
advantages compared to IMRT, such as significantly redu-
cing the treatment time and the number of MUs, as well as
improving normal tissue sparing while keeping adequate
coverage. Also, proton beams, unlike X-ray beams, have a
low entrance dose, followed by a region of uniform high
dose (the spread out Bragg peak) at the target, and then a
steep fall-off to zero dose. These characteristics minimize
the dose delivered to normal tissues while maximizing
the dose delivered to the tumor. Better or comparable dose
conformity with decreased low dose volume can be achieved
with proton beams than with advanced photon techniques
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[1–3]. This is because of the advantageous physical proper-
ties of protons, including a near zero exit or distal dose just
beyond the target volume, resulting in reduced proton
doses to normal tissue, with better conformation of the
dose to the target volume. These unique dose charac-
teristics of protons may reduce the risk of acute as well
as late side effects [4].
In recent years, several studies on treatment planning
or dosimetric validation with those obtained by proton
arc therapy (PAT) can be found in the literature [5, 6].
Rechner et al. [5] assessed the predicted risk of a second
cancer following proton arc therapy and VMAT technique
for prostate cancer. This study used proton arc plans with
16 equally spaced, static, passively-scattered proton beams.
They reported that the predicted risk of cancer for an out-
of-field organ such as the bladder or rectum following pro-
ton arc therapy is either less than or approximately equal to
the risk with VMAT. Seco et al. [6] compared a proton arc
technique using passively scattered beams and IMPT for
early-stage non-small cell lung cancer. Their study used 8–
14 beams with a maximum arc of 150°. They observed that
passive-arc therapy produced comparable tumor conform-
ity to VMAT and significantly reduced the low dose to the
lungs.
Although the proton arc technique has been reported
in the literature, extensive studies on treatment planning
or dosimetric validation of PAT plans have not yet been
conducted. Therefore, the purpose of the present study
was to compare dosimetric properties of PAT, PBT, and
IMRT techniques for tumors of the para-aortic lymph
nodes (PALN). We also compared the dose distribution,
organ equivalent doses (OED) and normal tissue complica-
tion probability (NTCP) resulting from IMRT, PBT, and
PAT techniques in the nine patients based on analysis of
dose-volume histograms (DVHs).
Methods and materials
Patient data and planning techniques
We randomly selected nine patients who were to be
treated with IMRT or PBT for PALN tumors at the Na-
tional Cancer Center (NCC) in Korea. The proton system
consists of a 230 MeV proton cyclotron, two gantries with
rotating beamlines and one gantry with a stationary hori-
zontal beamline. The two gantries with rotating beamlines
utilize passive scattering and uniform scanning delivery
techniques. The horizontal beam is usually used to treat
tumors of the eyes and prostate cases. The maximum ex-
tracted beam current of the cyclotron is 300 nA at a
106 Hz radio frequency. Minimum and maximum ranges
of the proton beam in water are 5 and 28 cm, respectively,
with 0.1 cm accuracy. When data from all nine patients
were analyzed, proton therapy was simulated to prescribed
dose with the beam range of 7.59 to 17.28 mm and a
modulation width of 5.48 to 11.78 mm.
For all patients, plans were designed on a CT scan (RT
16 PRO CT Simulator, General Electric Medical Systems,
Waukesha, WI) acquired with 2.5 mm slice thickness ex-
tending the scan from the 11th thoracic vertebral level to
include the proximal third of the femur’s diathesis. Pa-
tients were simulated in the supine position without a cus-
tom immobilization device, and these images were then
imported into Eclipse (version 10.0.28, Varian Medical
Systems, Palo Alto, CA) treatment planning system (TPS).
Gross tumor volumes (GTV) were determined based on
CT. Clinical target volumes (CTV) were considered to be
identical to the GTV. Planning target volumes (PTV) were
delineated as the CTV plus a 10 mm margin in all direc-
tions. The organs at risk (OAR) considered were: stomach,
small bowel, kidney, liver, and spinal cord. A total dose of
60 Gy was prescribed to the PTV, in 30 fractions of 2Gy
per fraction for all patients. Proton doses were corrected
with the accepted relative biologic effectiveness (RBE)
value of 1.1 [7]. The Eclipse pencil beam algorithm was
used to calculated dose. All treatment planning was calcu-
lated by using a tissue heterogeneities method and the grid
size of calculation was 2.5 mm.
The clinical IMRT plans were generated with 5–7 copla-
nar fields of a 6 MV photon beam. All IMRT optimiza-
tions were done by interactively adapting the objectives
and their priorities. A renal tolerance dose of 15 Gy (5 %
risk at 5 years) and 20 Gy (50 % risk at 5 years) was as-
sumed [8]. The hepatic tolerance dose (50 % risk at
5 years) was set at 30 Gy for the whole organ [9]. For the
spinal cord, a maximum dose objective of 45 Gy was ac-
cepted. The maximum dose objective for the stomach was
45 Gy for the entire organ.
The PBT and PAT techniques were generated using a
planning system developed specifically for the planning
of proton treatments using the so-called passive scatter-
ing technique. In systems that use beam scattering to
spread the beam, the small beam coming into the nozzle
is scattered to a large area, and the scatters are specially
designed so that the beam has a uniform penetration
and uniform intensity across the scattered area specified
for clinical use [10]. At the same time, the energy of the
beam is modulated to spread out the location of the Bragg
peaks over the target volume in depth. The system is usually
configured to produce a homogeneous dose distribution
with the same penetration across the beam. Passive scatter-
ing proton beams utilize physical patient field-specific hard-
ware, such as aperture and range compensator to obtain
better conformation of the dose to the target volume. The
patient aperture is a brass beam stop with a hole shaped to
the outer projection of the target in the beam’s eye view.
The range compensator is a plastic block and may be
designed for diverse clinical goals: guaranteeing target
coverage in the face of alignment error, patient and in-
ternal organ motion, and assuring the neighboring critical
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structures are spared [3]. For the PBT treatment planning,
two-field or three-field beams were used and the angles of
0 or 180 and 270 or 90 with ± 10° correction to avoid crit-
ical structures, especially the small bowel. Since PAT has
not been implemented to the current clinical application,
the purpose of treatment planning was to design, for each
treatment field, the aperture and range compensator, and
to specify the SOBP range, modulation and dose from the
virtual instrument of PAT. Eclipse TPS was used to split
the arcs into beam ports every 5°, resulting in 48 beam
ports for 240° arc. At NCC, proton beam energy uncer-
tainty used a systematic range of uncertainty of ± 0.6–
1.0 mm; however, because of the physical introduction of
patient field-specific hardware in the beam line, the repro-
ducibility of the range plus an additional ±1.0 mm for
both PBT and PAT.
Evaluation parameters
For each plan, DVHs were calculated for the PTV and
OARs. The coverage of PTV was calculated as the ratio
of target volume covered by 98 % isodose line divided by
the volume of PTV. Other criteria for PTV were the mean
dose (Dmean), D98%, D2%, (the percentage of prescribed
dose delivered to 98 and 2 % of the volume), conformity
index (CI) and homogeneity index (HI). The CI is the ratio
of target volume covered by 98 % isodose line divided by
the total volume covered by that isodose line. A conform-
ity index equal to 1 corresponds to ideal conformation. A
conformity index greater than 1 indicates that the irradi-
ated volume is greater than the target volume and in-
cludes healthy tissues. If the conformity index is less than
1, the target volume is only partially irradiated [11]. Ac-
cording to RTOG guidelines, ranges of conformity index
values have been defined to determine the quality of con-
formation, because a value of 1 is rarely obtained. If the
conformity index is between 1 and 2, treatment is consid-
ered to comply with the treatment plan [12]. The HI de-
scribes the uniformity of dose within a treated target
volume, and is directly calculated by the steepness of the
target DVH about the prescription dose, i.e. the difference
in dose received by 2 and 98 % of the PTV D2 −D98. Ac-
cording to this definition, D2 and D98 are considered the
maximum and minimum doses, respectively. If the HI
index is ≤2, treatment is considered to comply with the
RTOG protocol. A lower HI is indicative of a more homo-
geneous target dose. To quantify the dose distribution of
the OARs, V30%, V60%, V90% (the percentage of the vol-
umes receiving at least 30 %, 60 %, and 90 % of the pre-
scribed dose), and Dmean were evaluated.
DVHs were also analyzed in terms of OEDs and NTCPs
for the OARs. When analyzing high or medium dose
levels organs typically receive inhomogeneous dose distri-
butions. To consider such effect, one might use the con-
cept of OED, in which any dose distribution corresponds
to the same OED if it causes the same radiation-induced
cancer risks. A risk factor is then applied to the OED [13,
14]. Parameters for OED are the organ-specific cancer in-
cidence rate at low doses, which can be taken from the
data of the atomic bomb survivors, and cell sterilization at
higher doses [15]. If the true dose–response curves for
radiation-induced cancer were known for each organ and
tissue, an OED estimate would be a perfect parameter to
quantify second cancers. However, because the underlying
dose–response function is not known, several models have
been used. One can thus assume three dose–response re-
lationships, linear, bell-shaped, and plateau-shaped using
free model parameter aorgan and δorgan [16] as follows:
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where V is the total organ volume and the sum is taken
over all volume element Vi with homogeneous dose Di.
Since for small doses the dose–response relationship for
cancer induction is with good precision a linear function of
dose, OED is simply average orang dose. However, for high
doses there is currently much debate concerning the shape
of the dose–response curve for radiation-induced cancer
[16]. In this study, all three models were presented; how-
ever, to estimate secondary cancer risk for the three tech-
niques, we used a plateau dose–response model, which is
located approximately in the middle of the two extreme
models.
The NTCP was computed using the Lyman Kutcher
Burman (LKB) model to ascertain the expected incidence
of complications [17]. It consists of a probit equation as
the relation between a dose of uniform radiation and the
probability of effect. This is combined with an equivalent
uniform dose (EUD) DVH reduction method [18]. NTCP
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Di and vi are N pairs of dose level and corresponding
subvolume (relative to the total organ volume) of the dif-
ferential DVH. Three model parameters (D50, m, and n)
can be found in these expressions. D50 is the uniform dose
corresponding to 50 % complication probability and m is
the slope of the dose–response curve at that position. The
volume effect is accounted for by parameter n. A special
case of the LKB model is the mean dose model where n is
fixed at a value of 1. In order to calculate OED and NTCP,
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DVH data from each plan was analyzed by using the tool
developed with home-made software [19].
The PAT plan was each compared with the IMRT
and PBT plans with regard to DVHs and doses to
OARs. The paired t test was used for all statistical
comparisons, with a p values of ≤0.05 considered sig-
nificant; p values of < 0.001 were truncated and noted
as p < 0.001.
Results
Figure 1a, b and c shows the IMRT, PBT and PAT calcu-
lated dose distributions of one patient with PALN tumor,
respectively, and then the DVH curves for PTV and
OARs of each technique are shown in Fig. 2. Comparing
the dose distributions, the PAT plan shows a good con-
formation of the target volume, with a maximum dose
in the target of 106 %. Detailed dosimetric comparisons
of the PTV and various OARs for the three techniques,
based on DVHs analysis is shown in Table 1. Data are pre-
sented as averages over the nine investigated patients and
errors indicate inter-patient variability at the 1 standard de-
viation level. PAT plans had excellent coverage of the PTV
with ≥99.6 % of the PTV receiving ≥98 % of the prescribed
dose. The CI obtained with PAT was 1.19 ± 0.02, which
was significantly better than that for IMRT techniques (p <
0.001). The HI was also lowest for PAT plan and highest
for IMRT (p = 0.003). Dmean of the PTV was equal for all
three techniques (IMRT vs. PAT (p = 1.000), PBT vs. PAT
(p = 0.371)), whereas D2% was smallest for PAT and highest
for IMRT plan (p = 0.002). Doses to the OAR were below
the acceptable limits and comparable for all three tech-
niques. The PBT technique reduced the Dmean more than
IMRT techniques in the OAR (p = 0.045), which was simi-
lar to those of PAT (p = 0.692). However, the average OARs
volume percentage receiving 30 % of the prescribed dose
(V30%) was generally lower for PAT compared to PBT for
considered OARs (p = 0.393).
Figure 3 shows the relative OEDs calculated based
on a linear, bell-shaped and plateau dose–response
model for PALN tumor treatment. The calculated OEDs
for the stomach, small bowel, kidney, liver, and spinal cord
were normalized to the OEDs of IMRT treatment to
determine differences that might be seen when using
PBT or PAT. In our results, the risk for IMRT is en-
hanced in the OARs when applying a bell-shaped and
plateau dose–response relationship; however, it is not
enhanced for a linear model. For OED calculated with
the plateau model, the secondary cancer risks to the
OARs were generally lower using PAT than using
PBT technique. The OEDs from the IMRT technique
were nearly three times higher than those from PAT
technique.
The calculated values of NTCP for the OARs are
shown in Fig. 4 for the three techniques. The estimated
NTCP for the kidney as well as for the spinal cord was
negligible for any of the treatment techniques and is not
shown. In all the investigated OARs, the IMRT tech-
nique showed the highest NTCPs. PAT plans reduced
NTCP substantially compared to the conventional PBT
technique, and our NTCP data for the liver were very
similar in both proton plans.
Fig. 1 Dose distribution of (a) IMRT, (b) PBT, and (c) PAT technique
in axial plane. Color wash banding is restricted to relative dose
range of 11–110 %
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Fig. 2 Dose-volume histograms for (a) planning target volume (PTV), (b) stomach, (c) small bowel, (d) kidney, (e) liver, and (f) spinal cord, comparing
IMRT, PBT, and PAT techniques
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Discussion
Our findings indicate that PAT resulted in improvements
in most dosimetric parameters for PALN tumor pa-
tients compared with the IMRT and PBT techniques.
The recommendations of our radiation therapy oncology
group for dose homogeneity are as follows: no more than
20 % of any PTV will receive > 110 % of the prescribed dose
and the prescription dose is the isodose that encompasses
at least 95 % of the PTV [20]. This suggests that, for an ac-
ceptable plan, 95 and 110 % may be safely taken as the
minimum (D98% PTV) and maximum (D2% PTV) doses,
respectively. When compared with conventional proton
beam plans, PAT technique showed excellent dosimetric re-
sults for target coverage, conformity, and homogeneity. PAT
also decreased the average OARs volume percentage re-
ceiving 30 % of the prescribed dose (V30%) compared
with PBT and IMRT. Theoretically, PAT technique
has the potential to achieve these normal tissue con-
straints while permitting dose escalation to the grossly
enlarged metastatic lymph nodes in the para-aortic area,
which was similar to those of other new normal tissue-
sparing techniques, such as stereotactic body radiation
Table 1 Plan comparison between IMRT, PBT and PAT. (average of nine patients)
IMRT PBT PAT P*
PTV
Coverage (%) 98.5 ± 0.02 99.0 ± 0.01 99.6 ± 0.01 IMRT vs. PAT (1.000), PBT vs. PAT (0.145)
D2% (Gy) 63.2 ± 0.04 62.8 ± 0.04 62.4 ± 0.02 IMRT vs. PAT (0.002), PBT vs. PAT (1.000)
D98% (Gy) 59.1 ± 0.05 59.4 ± 0.01 59.8 ± 0.02 IMRT vs. PAT (1.000), PBT vs. PAT (1.000)
Dmean (Gy) 61.9 ± 0.02 61.4 ± 0.03 61.6 ± 0.03 IMRT vs. PAT (1.000), PBT vs. PAT (0.371)
Conformity index (CI) 1.47 ± 0.03 1.23 ± 0.03 1.19 ± 0.02 IMRT vs. PAT (<0.001), PBT vs. PAT (1.000)
Homogeneity index (HI) 6.83 ± 0.02 5.67 ± 0.01 4.33 ± 0.02 IMRT vs. PAT (0.003), PBT vs. PAT (<0.001)
Stomach
V30% (%) 41.5 ± 4.1 26.4 ± 14.3 23.7 ± 8.1 IMRT vs. PAT (<0.001), PBT vs. PAT (<0.001)
V60% (%) 12.5 ± 1.5 14.8 ± 5.4 11.3 ± 5.6 IMRT vs. PAT (<0.001), PBT vs. PAT (0.018)
V90% (%) 0.09 ± 0.4 4.25 ± 2.1 3.15 ± 0.9 IMRT vs. PAT (<0.001), PBT vs. PAT (0.002)
Dmean (Gy) 16.2 ± 1.6 9.84 ± 3.2 10.1 ± 8.4 IMRT vs. PAT (<0.001), PBT vs. PAT (0.518)
Small bowel
V30% (%) 26.2 ± 7.5 17.5 ± 10.2 12.7 ± 4.2 IMRT vs. PAT (<0.001), PBT vs. PAT (<0.001)
V60% (%) 2.50 ± 4.2 0.63 ± 4.3 0.73 ± 1.1 IMRT vs. PAT (<0.001), PBT vs. PAT (0.327)
V90% (%) 0.20 ± 1.3 0.11 ± 1.2 0.02 ± 0.4 IMRT vs. PAT (0.402), PBT vs. PAT (0.039)
Dmean (Gy) 18.7 ± 1.1 14.9 ± 2.9 15.8 ± 1.9 IMRT vs. PAT (0.365), PBT vs. PAT (0.521)
Kidney
V30% (%) 12.0 ± 6.3 0.96 ± 2.4 1.10 ± 3.5 IMRT vs. PAT (<0.001), PBT vs. PAT (0.960)
V60% (%) 1.46 ± 3.9 0 0 IMRT vs. PAT (0.053), PBT vs. PAT (0.321)
V90% (%) 0.36 ± 1.4 0 0 IMRT vs. PAT (1.000), PBT vs. PAT (1.000)
Dmean (Gy) 6.61 ± 2.9 1.10 ± 3.3 2.41 ± 2.6 IMRT vs. PAT (1.000), PBT vs. PAT (0.412)
Liver
V30% (%) 10.5 ± 0.9 8.91 ± 6.7 8.02 ± 4.5 IMRT vs. PAT (<0.001), PBT vs. PAT (1.000)
V60% (%) 0.16 ± 0.7 2.16 ± 2.6 1.62 ± 1.7 IMRT vs. PAT (<0.001), PBT vs. PAT (0.852)
V90% (%) 0.02 ± 0.4 0.02 ± 1.3 0.05 ± 1.5 IMRT vs. PAT (0.532), PBT vs. PAT (1.000)
Dmean (Gy) 10.6 ± 0.4 7.38 ± 1.9 7.88 ± 1.2 IMRT vs. PAT (1.000), PBT vs. PAT (1.000)
Spinal cord
V30 % (%) 29.7 ± 7.7 21.5 ± 9.4 0 IMRT vs. PAT (<0.001), PBT vs. PAT (<0.001)
V60 % (%) 8.68 ± 8.2 0 0 IMRT vs. PAT (<0.001), PBT vs. PAT (1.000)
V90 % (%) 0 0 0 IMRT vs. PAT (1.000), PBT vs. PAT (1.000)
Dmean (Gy) 15.0 ± 4.2 6.21 ± 6.5 0.92 ± 0.7 IMRT vs. PAT (<0.001), PBT vs. PAT (1.000)
Abbreviations Dx%dose received by the x% of the volume, Vx% volume receiving at least x% of the prescribed dose. Average parameters ± standard deviation (k = 1)
are displayed
*p values of ≤0.05 considered significant; p values of <0.001 were truncated and noted as p < 0.001
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therapy (SBRT). This study provides further evidence
that PAT reduces the risk of radiation side effects be-
cause of its superior dosimetric properties.
For the three techniques, we calculated the OED of
the OARs. Since OED is directly proportional to the risk
of radiation induced cancer different treatment modal-
ities can be compared with respect to their carcinogenic
potential. One of the main advantages of conventional
proton beam may be the reduced risk of radiation induced
secondary malignancy. Secondary cancer risk after pros-
tate and head-and-neck radiotherapy shows the already
observed behavior of a modest increase for IMRT than
those of proton therapy [21]. Mu et al. [22] estimated the
risk of radiation-induced cancer after spinal irradiation for
childhood medulloblastoma, and found that the life time
risk of secondary cancer was approximately eightfold less
when intensity modulated proton therapy (IMPT) was
used, compared with IMRT. Recently, another study has
Fig. 3 Relative organ equivalent dose (OED) of the (a) stomach, (b) small bowel, (c) kidney, (d) liver, and (e) spinal cord, using IMRT, PBT and PAT
technique to treat nine patients, normalized relative to OEDs of IMRT, using three calculation models
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shown that the estimated secondary cancer risk associated
with proton beams in the treatment of pediatric tumor
ranged from 0.6 to 1.5 [23]. In our results, the average
OEDs calculated according to a plateau model, after PAT
was found in practice to be 0.57, which shows that the
secondary malignancy risk associated with PAT is close to
that of PBT. This suggests that the risk of secondary can-
cer after PAT is roughly the same as that after PBT. These
estimations are relatively consistent with respect to previ-
ously reported data; our results include a certain level of
uncertainty as the real incidence of secondary cancers
after radiation treatment is not definitively known. Al-
though risk estimations will vary with the model chosen,
PBT or PAT seem to minimize secondary cancer risk if
one assumes that the lower the radiation dose to OARs,
the less the incidence of secondary cancers.
NTCP represents the complication probability of normal
organs exposed to radiation. In a recent treatment planning
study, the arc technique, such as VMAT distributes lower
dose over a larger volume of normal tissue than a static
IMRT plan [24]. They showed that VMAT allows one to
keep the same PTV coverage with an improved homogen-
eity and better conformality and, at the same time, pre-
sented a major reduction of irradiation of bladder, rectum
and small bowel over the entire medium to high dose levels
with highly statistically significant differences. If expected
toxicity at 50 Gy can be low, the NTCP estimates showed
that VMAT, assuming the same quality of plans, could
allow some dose escalation process keeping the relative
complication risk much smaller than IMRT. In our study,
the NTCPs of PAT technique are 0.29 % (stomach), 0.69 %
(small bowel), and 0.38 % (liver). It would be possible with
a similar sophisticated approach in PAT to further reduce
the dose to the PALN tumor. The NTCP estimates showed
that PAT, assuming the same quality of plans, could allow
some dose escalation process while keeping the relative
complication risk low. Altogether, the findings suggest that
PAT should be considered as a treatment option for PALN
patients and likely for a wide group of abdomen indications
(including pancreas, kidney, and liver treatments).
The present study has a few important issues. One issue
is that we used approximately 48 beams of one ration for
the PAT plans; this means it is needs to be designed for
each treatment field, the range modulator and compensa-
tor. It would be impractical to deliver these plans in pa-
tients using currently-available passive systems. However,
it is possible that the alternative method will be found to
reduce the number of arc beams for conventional passive
scattering beams. This approach was similar to that of
Seco et al. [6], who used 8–14 passive-arc beams. Strictly
speaking of course, field-specific range compensators are
not required for the pencil beam scanning, as the pull-
back Bragg peaks can be achieved by an energy adjust-
ment, but they may be useful in terms of the resolution
[10, 25]. The spatial resolution of a compensator, typically
3 mm, compares favorably to the size of pencil beams
available for IMPT treatments with FWHM of 10 mm and
higher. These pencil beam widths are primarily controlled
by the beam line magnets but are adversely affected by the
traversal of the proton beam through materials to reach
the patient. The high lateral resolution of the range com-
pensator, combined with a depth resolution of better than
1 mm, may allow for better conformality to the distal tar-
get surface than can be achieved with the energy modula-
tion alone. In IMPT, the number of required irradiation
layers may be reduced with the use of compensator. Re-
cently, a variety of devices have become available for scat-
tering and range compensation. An innovative method to
make patient-specific hardware, such as the range com-
pensator would be to use low cost 3-dimensional printer.
This approach reduces manufacturing times with more ef-
ficient cuts and a more personalized process than a com-
puterized milling machine.
The other issue of PAT plans necessarily requires a
number of material components in the beamline, specific-
ally scatters and collimators, proton interactions with
these components result in the production of high-energy
secondary neutrons. This is not just a PAT issue; in gen-
eral, the conventional passive scattering systems have their
limitations. To date, we have considered only the primary
doses shown by the TPS. However, accurate comparisons
of radiation-induced carcinogenesis among treatment mo-
dalities should also include calculations of secondary
doses, such as the leakage dose in photon beam and the
neutron dose in proton beam [21, 26]. Although proton
therapy may result in reduced exposure of adjacent nor-
mal tissue to high and intermediate doses, the therapy
may nonetheless result in an increase in low doses to the
rest of the body (because of neutrons produced by the
scattering components of passive scattering proton beams)
which exceed those resulting from conventional photon
Fig. 4 Relative normal complication probability (NTCP) of the stomach,
small bowel, and liver using IMRT, PBT technique and PAT to treat
nine patients
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treatment. Some technical issues, such as proton scatter-
ing from apertures, have been skipped as well [25]. In par-
ticular, most proton collimators are currently made out of
brass or cerrobend which are high atomic mass material; a
collimator made out of low mass material could signifi-
cantly decrease the neutron dose and thus the cancer risks
associated with secondary neutrons.
The clinical and practical use of PAT is still limited and
technologically unique but clearly emerging as a desired
and required mode for alternative treatment technique in
proton beam. The PAT is accepted as important comple-
mentary methods to the conventional passive scattering
and pencil scanning techniques. Of course the pencil beam
scanning is a precise and efficient method as no field spe-
cific hardware is needed. The disadvantage of scanning is
the higher sensitivity to organ motion compared to passive
scattering [25]. The sensitivity to organ motion errors is the
main reason why only well immobilized tumors- located in
the head and neck, spinal cord and lower pelvis- have been
treated using a scanning technique. Organ motion is there-
fore the single most important motivation to improve the
utilization of scanning techniques. A major effort in the de-
velopment of fast scanning techniques is needed to apply
conformal beam scanning with a reasonably high number
of target repainting. As a backup solution one should also
develop simulated scattering. The approach to use a scan-
ning system as the basic equipment could become in the
near future practical steps, as scanning can create any dose
distribution produced in a scattered beam [25]. The recent
study also reported that the proton RBE exhibits a linear
energy transfer (LET)-dependency and that this could play
a role in treatment planning [27]. It suggested that proton-
modulated arc therapy might allow simultaneous dose and
LET painting of a target while delivering the dose in an
efficient manner. We plan to examine the feasibility of per-
forming proton-modulated arc therapy, choosing to com-
pare simple passive-arc beam that clearly demonstrate the
physical and biological properties of intensity-modulated
arc beam used. This approach is possible that it provides a
solution to the organ motion problem in pencil beam
scanning.
Conclusion
This study demonstrates that there is a potential role for
PAT as an alternative technique to conventional proton
therapy. PAT is not yet clinically available, but it will be
more efficient and safer treatment in the future with add-
itional research and development for commercialization.
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